PLRX Stock Summary and Trading Ideas (Pliant Therapeutics | NASDAQ:PLRX)

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics trades on the NASDAQ stock market under the symbol PLRX.

As of February 12, 2026, PLRX stock price declined to $1.13 with 495,320 million shares trading.

PLRX has a beta of 1.38, meaning it tends to be more sensitive to market movements. PLRX has a correlation of 0.03 to the broad based SPY ETF.

PLRX has a market cap of $69.44 million. This is considered a Micro Cap stock.

In the last 3 years, PLRX traded as high as $32.47 and as low as $1.09.

The top ETF exchange traded funds that PLRX belongs to (by Net Assets): VTI, VXF, IWC, VHT, PRFZ.

PLRX has underperformed the market in the last year with a price return of -58.5% while the SPY ETF gained +14.1%. PLRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.2% and -8.9%, respectively, while the SPY returned 0.0% and -1.8%, respectively.

PLRX support price is $1.11 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLRX shares will trade within this expected range on the day.